Literature DB >> 11115538

Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma.

T Ueno1, O Hashimoto, R Kimura, T Torimura, T Kawaguchi, T Nakamura, R Sakata, H Koga, M Sata.   

Abstract

Hepatocarcinogenesis is closely related to hepatic fibrosis. In this study, we investigated the relationship of type II transforming growth factor-beta receptor (T beta RII) to hepatic fibrosis and hepatocellular carcinoma (HCC). In vivo: liver tissues were obtained from 30 patients (10 chronic hepatitis, 7 cirrhosis, 13 HCC). Protein expression and immunolocalization of T beta RII were examined by Western blot analysis and immunohistochemistry. In vitro: T beta RII protein expression in hepatoma cell lines (HepG2, Hep3B, HLE, HLF and Huh7) was examined by Western blot analysis. Next, we transfected T beta RII cDNA to Huh7, and compared the change of cell number and observed the induction of apoptosis after TGF-beta1 treatment using a FACScan flow cytometer. In vivo: T beta RII immunolocalization in liver tissues was significantly decreased in patients with HCC compared with that of patients with chronic hepatitis or liver cirrhosis. In Western blot analysis, T beta RII expression in tissues attenuated in comparison with that in non-tumor tissues in some patients with HCC. In vitro: T beta RII protein expression in HLE, HLF and Huh7 cells was weaker than that in HepG2 and Hep3B cells. In Huh7 cells transfected T beta RII cDNA, cell arrest and apoptosis were obviously induced. These results indicated that human HCC has a reduced expression of T beta RII for TGF-beta1. This may provide a selective growth advantage to HCC to escape the inhibitory growth signals of TGF-beta1, and may be linked with critical steps in the growth of hepatoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11115538     DOI: 10.3892/ijo.18.1.49

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

Review 1.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.

Authors:  Guo-Zhong Ji; Xue-Hao Wang; Lin Miao; Zheng Liu; Ping Zhang; Fa-Ming Zhang; Jian-Bing Yang
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

3.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01

4.  FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.

Authors:  Zhixin Chen; Bao Xie; Qinhua Zhu; Qinghai Xia; Songmin Jiang; Ruoyu Cao; Lihua Shi; Dansi Qi; Xiaokun Li; Lin Cai
Journal:  Int J Med Sci       Date:  2013-11-12       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.